Michael Stumpp

Executive Vice President - Projects Molecular Partners

Seminars

Thursday 3rd December 2026
Beyond Peptides: Advancing Radio-DARPin Therapeutics from Platform Innovation to Clinical Proof-of- Concept
1:30 pm
  • Presenting imaging and dosimetry insights from MP0712, a DLL3-targeted Pb-212 Radio-DARPin Therapeutic currently in Phase I development
  • Exploring how half-life extended Radio-DARPins are designed to overcome the limitations of conventional peptide-based radiopharmaceutical approaches for challenging targets
  • Sharing key learnings from advancing a novel targeted alpha therapy approach across clinical and preclinical development programmes
Michael Stumpp